Last reviewed · How we verify
ProQuad®
ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses.
ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses. Used for Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older.
At a glance
| Generic name | ProQuad® |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
ProQuad contains weakened (attenuated) strains of measles, mumps, rubella, and varicella-zoster viruses. When administered, these live vaccine viruses replicate in the body at a limited level, triggering both humoral and cell-mediated immune responses that generate protective antibodies and cellular immunity against all four diseases without causing the actual diseases.
Approved indications
- Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older
Common side effects
- Injection site reactions (erythema, swelling, tenderness)
- Fever
- Rash
- Varicella-like rash
- Parotitis
- Measles-like rash
Key clinical trials
- Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant (EARLY_PHASE1)
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) (PHASE4)
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age (PHASE2)
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (PHASE3)
- ProQuad® Intramuscular vs Subcutaneous (PHASE3)
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM (PHASE3)
- Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (PHASE3)
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |